Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Sepantronium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BIRC5 | O15392 | 1/20 | 0.98 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.98 |
| ▸ | SP1 | P08047 | 1/20 | 0.98 |
| ▸ | ILF3 | Q12906 | 1/20 | 0.98 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.98 |
| ▸ | CDK4 | P11802 | 1/20 | 0.35 |
| ▸ | CCND1 | P24385 | 1/20 | 0.35 |
| ▸ | CCND2 | P30279 | 1/20 | 0.35 |
| ▸ | CCND3 | P30281 | 1/20 | 0.35 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sepantronium SCHEMBL2814857 | 1.00 | BIRC5 (0.98) | BIRC5RIPK2SP1ILF3PAK1 | |
| Sepantronium SCHEMBL29493286 | 0.99 | BIRC5 (1.00) | BIRC5RIPK2SP1ILF3PAK1 | |
| Sepantronium SCHEMBL727997 | 0.99 | BIRC5 (1.00) | BIRC5RIPK2SP1ILF3PAK1 | |
| Bromide SCHEMBL15062823 | 0.87 | BIRC5 (0.79) | BIRC5RIPK2SP1ILF3PAK1 | |
| SCHEMBL6190071 | 0.86 | BIRC5 (0.74) | BIRC5RIPK2SP1ILF3PAK1 | |
| SCHEMBL6190207 | 0.85 | BIRC5 (0.72) | BIRC5RIPK2SP1ILF3PAK1 | |
| Sepantronium SCHEMBL29464041 | 0.84 | BIRC5 (0.71) | BIRC5RIPK2SP1ILF3PAK1 | |
| Sepantronium SCHEMBL6188375 | 0.84 | BIRC5 (0.71) | BIRC5RIPK2SP1ILF3PAK1 | |
| Sepantronium SCHEMBL16584072 | 0.83 | BIRC5 (0.73) | BIRC5RIPK2SP1ILF3PAK1 | |
| Sepantronium SCHEMBL29379252 | 0.83 | BIRC5 (0.73) | BIRC5RIPK2SP1ILF3PAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1614686-B1 | BROMIDE AND ITS CRYSTAL | ASTELLAS PHARMA INC (JP) | 2014-05-07 | — | — | EP | disclosed |
| US-20100249413-A1 | STABILIZED PHARMACEUTICAL COMPOSITION | ASTELLAS PHARMA INC. (JP) | 2010-09-30 | — | — | US | disclosed |
| EP-2055304-A1 | STABILIZED PHARMACEUTICAL COMPOSITION | Astellas Pharma Inc. (JP) | 2009-05-06 | — | — | EP | disclosed |
| US-20060223831-A1 | Bromide and its crystal | ASTELLAS PHARMA INC. (JP) | 2006-10-05 | — | — | US | disclosed |
| EP-1614686-A1 | BROMIDE AND ITS CRYSTAL | Astellas Pharma Inc. (JP) | 2006-01-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223831-A1 | Bromide and its crystal | B2M, PBRM1, POLM | BIRC5 1109/4885RIPK2 3146/4885SP1 4106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.